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Despite significant advances in the use of surgery, chemotherapy and radiotherapy to treat squamous cell carcinoma of the head and
neck (SCCHN), prognosis has improved little over the past 30 years. There is a clear need for novel, more effective therapies to
prevent relapse, control metastases and improve overall survival. Improved understanding of SCCHN disease biology has led to the
introduction of molecularly targeted treatment strategies in these cancers. The epidermal growth factor receptor (EGFR) is
expressed at much higher levels in SCCHN tumours than in normal epithelial tissue, and EGFR expression correlates with poor
prognosis. Therefore, much effort is currently directed toward targeting aberrant EGFR activity (e.g. cell signalling) in SCCHN. This
review discusses the efficacy of novel therapies targeting the EGFR (e.g. anti-EGFR antibodies and EGFR tyrosine kinase inhibitors)
that are currently tested in SCCHN patients.
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Head and neck cancer (HNC) accounts for about 5% of all cancers
with 4500000 cases diagnosed worldwide and 4100000 in
Europe each year. The majority of HNC in the Western world is
of squamous cell origin (490% squamous cell carcinoma of the
head and neck, SCCHN) and present with locally or regionally
advanced disease (Rogers et al, 2005). Patients with early-stage
disease are treated with surgery and/or radiotherapy and nearly
80% are cured. Chemotherapy added to locoregional treatment
provides a demonstrated survival benefit in nonmetastatic SCCHN
(Pignon et al, 2000). However, despite combined treatment
approaches (surgery and radiation/chemoradiation therapy) most
patients with resectable advanced disease develop local or regional
recurrences (50–60%), metastatic disease (B20%) or secondary
primaries. Patients with unresectable advanced disease have a
5-year survival of o10% and recurrent/metastatic cases have a
median survival of approximately 6–9 months, which has not
changed significantly for 30 years. Several therapeutic options
are available for these patients, including (re-)irradiation, salvage
surgery, palliative chemotherapy or best supportive care for
patients with low performance status. The most commonly used
agents are cisplatin or carboplatin, often in combination with
taxanes or 5-fluorouracil. Response rates (RR) to first-line
platinum-based chemotherapy are only B30%. In recurrent/
metastatic SCCHN, survival benefits of 10 weeks may be expected
(Morton et al, 1985; Browman and Cronin, 1994). Although several
combinations of classical chemotherapeutics have increased RR,
improved survival has not been observed. Options and RR of
patients refractory to platinum-based therapies are generally very
poor. Therefore, there is clearly an unmet therapeutic need for new
active, less toxic agents for SCCHN treatment.
TARGETING EPIDERMAL GROWTH FACTOR-
RECEPTOR SIGNALLING IN SCCHN
Several molecularly targeted strategies have been evaluated in HNC
patients owing to (1) mechanism of action, (2) greater selectivity
and (3) different/lower toxicity. Potential targets are growth factor
receptors, signal transduction, cell cycle control, protein degrada-
tion, hypoxia, angiogenesis and prostaglandin synthesis. The
epidermal growth factor-receptor (EGFR) is a particularly inter-
esting target as it plays an important role in regulation of cellular
proliferation, differentiation and survival of epithelial cells and
tumours of epithelial cell origin. Additionally, aberrant EGFR
signalling imparts SCCHN cells with classic tumour cell character-
istics, including decreased apoptosis, enhanced invasiveness,
migration, angiogenesis and metastasis. Furthermore, EGFR is
overexpressed in approximately 90–100% of SCCHN specimens
and has been associated with worse prognosis, including advanced
stage, poorly differentiated tumours and poor survival (Santini
et al 1991; Dassonville et al, 1993). Epidermal growth factor-
receptor is one of four transmembrane growth factor receptors
that share structural and functional similarities, including EGFR
(¼HER1, c-erbB-1), HER-2/neu (c-erbB-2), HER3 (c-erbB-3) and
HER4 (c-erbB-4). The EGFR, a 170kDa glycoprotein, consisting
of an extracellular domain, a transmembrane region and an
intracellular domain with tyrosine kinase function, responds to
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a), betacellulin, amphiregulin, epiregulin, EGF and heparin-
binding EGF (Rogers et al, 2005).
Downstream effects of EGFR activation after receptor dimerisa-
tion, internalisation and autophosphorylation are mediated
through several signal transduction pathways involving the RAS/
MAP kinase, the phosphatidylinositol 3-kinase (PI-3K)/Akt, the
PLCg and the JAK-STAT pathways (Rogers et al, 2005; Kalyank-
rishna and Grandis, 2006) (Figure 1). Although the main
autophosphorylation sites in ErbB receptors recruit extensively
overlapping molecules to the active receptors, preferential
modulation of signalling pathways seems to occur (e.g. EGFRs
with kinase-domain mutations preferentially activate the pro-
survival PI-3K/AKT pathway and the STAT pathway). Downstream
effectors of EGFR (e.g. ERK-1/2, AKT, STAT-3/5) are activated in
SCCHN (Kalyankrishna and Grandis, 2006). Epidermal growth
factor receptor ligand binding results in several homo- or
heterodimeric complexes. Furthermore, EGFR can be activated
by other receptor tyrosine kinases including insulin-like growth
factor-1 receptor, adhesion molecules (e.g. E-cadherin and
integrins) and G-protein-coupled receptors (GPCR).
Deregulation of EGFR function is a common feature in several
human malignancies including lung, breast, colorectal, prostate
and HNC. Mechanisms of EGFR activation include (1) receptor
overexpression in most epithelial malignancies (EGFR in up to
90% of SCCHN; ErbB2 in 3–29%; ErbB3 in 21% and ErbB4 in
26%), (2) constitutively activated EGFR mutants, (3) autocrine
activation by ligand overexpression (e.g. TGF-a), (4) ligand-
independent activation through other receptor systems (e.g.
ErbB2/HER2), (5) EGFR transactivation by GPCR-induced proces-
sing of transmembrane growth factor precursors by ADAM family
metalloproteases, (6) gene amplification and/or (7) loss of negative
regulatory mechanisms (Rogers et al, 2005; Kalyankrishna and
Grandis, 2006).
Dysregulated p53, polymorphisms in dinucleotide repeats in
intron 1 of the EGFR gene and EGFR amplification can all lead to
increased EGFR mRNA synthesis. However, EGFR gene amplifica-
tion was only observed in seven out of 33 patients with SCCHN
and did not correlate with EGFR protein overexpression, suggest-
ing that gene amplification is not pathogenetically involved in
EFGR protein overexpression (Mrhalova et al, 2005). Furthermore,
overexpression of cortactin may inhibit ligand-induced EGFR
downregulation. Interestingly, tobacco smoke increases
EGFR ligand levels (e.g. amphiregulin, TGF-a) culminating in
EGFR activation and increased levels of cyclooxygenase 2 and
prostaglandin E2, which can transactivate EGFR (Kalyankrishna
and Grandis, 2006).
Recently, three identical in-frame deletions in exon 19
(E746_A750del) of the EGFR gene were reported in three out of
41 (7.3%) Korean SCCHN cases (Lee et al, 2005). In contrast,
EGFR kinase domain mutations were rare among US (zero out of
65) or European (one out of 100) SCCHN cases (Cohen et al, 2005a;
Loeffler-Ragg et al, 2006). Interestingly, one gefitinib-responsive
SCCHN patient harboured a heterozygous mutation within ErbB2
(V773A) (Cohen et al, 2005a). ErbB2 heterodimerises with EGFR
and ErbB2 mutations have recently been reported within a subset
of non-small cell lung cancer (NSCLC). Epidermal growth factor
receptor vIII, a deletion of exons 2–7 resulting in a truncated
extracellular domain and constitutive tyrosine kinase activation,
has been reported in glioblastoma multiforme (450%; Moscatello
et al, 1995), NSCLC (1–42%; Ji et al, 2006; Sonnweber et al, 2006)
and in SCCHN (42%; Sok et al, 2006).
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Figure 1 Intracellular signalling of the EGFR. Shown are the major signalling pathways downstream of c-erbB-receptors (e.g. EGFR). Modified after Rogers
et al (2005) and Kalyankrishna and Grandis (2006). Binding of specific ligands (e.g. EGF, heparin-binding EGF, TGF-a, amphiregulin, betacellulin and heregulin)
may generate up to 10 types of homo- or heterodimeric complexes resulting in conformational changes in the intracellular EGFR kinase domain, which lead
to autophosphorylation and activation. Consequently, signalling molecules, including growth factor receptor-bound protein-2 (Grb-2), Shc and IRS-1 are
recruited to the plasma membrane. G-protein coupled receptors can also activate EGFR in a ligand-independent manner by Src-mediated direct
phosphorylation of Y-845. Insulin-like growth factor-1 receptor can also transactivate the EGFR. Activation of several signalling cascades is triggered
predominately by the RAS-to-MAPK and the PI-3K/Akt pathways, resulting in enhanced tumour growth, survival, invasion and metastasis.
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Several approaches to block EGFR signalling in human diseases
have been tested, including (1) monoclonal antibodies (Mabs), (2)
small molecule tyrosine kinase inhibitors (TKIs), (3) inhibition of
receptor trafficking to the cell membrane and (4) inhibition of
EGFR synthesis through antisense oligonucleotides. Only Mabs
against EGFR and EGFR-specific TKIs have been evaluated in
phase III trials (Figure 2). Inhibition of EGFR signalling has been
used in primary treatment of locally advanced SCCHN with
radiation therapy and as first/second-line agents in recurrent/
metastatic SCCHN.
Anti-EGFR Mabs
EGFR-specific Mabs and their characteristics are listed in Table 1.
Mechanisms of action include (1) inhibition of receptor activation
and signalling by blocking ligand binding to the extracellular
domain, and (2) induction of antibody-dependent cell-mediated
cytotoxicity and/or complement-dependent cytotoxicity.
Anti-EGFR Mabs in recurrent/metastatic SCCHN Cetuximab
(IMC-C225) has antitumour activity against several tumour cell
lines expressing EGFR and in SCC tumour xenograft models.
Cetuximab has been studied in several phase I–III trials in
locoregionally advanced or recurrent/metastatic SCCHN patients
(Table 2). In three phase I trials (including 26 SCCHN patients) of
cetuximab as a single, weekly multiple dose (5–400mgm
 2) with
or without cisplatin (60mgm
 2 once every 4 weeks), disease
stabilisation was observed without reaching MTD. Nine out of 13
patients treated with cetuximab doses X50mgm
 2 plus cisplatin
completed 12 weeks of therapy including two partial responses
(PRs) in SCCHN after treatment with 200 and 400mgm
 2 (Baselga
et al, 2000). Another phase Ib study combining cetuximab with
cisplatin in recurrent SCCHN reported two complete remissions
(CRs) and four PRs of nine patients (Shin et al, 2001). The most
frequently occurring adverse events (AEs) were fever/chills,
asthenia, transaminase elevation, nausea and skin toxicities
including acneiform rashes, flushing and seborrheic dermatitis.
Grade 3–4 AEs included aseptic meningitis, allergic reaction,
epiglottitis plus dyspnoe.
Antitumour activity of cetuximab plus cisplatin in platinum-
refractory SCCHN patients was recently reported. In a multicentre
phase II trial, 132 SCCHN patients were treated with two 3-week
cycles of cisplatin/paclitaxel or cisplatin/5-fluorouracil (Herbst
et al, 2005). Patients with a CR or PR continued standard therapy.
Patients with stable disease (SD; n¼51) or progressive disease
(PD/1; n¼25) received cetuximab plus cisplatin (75 or 100mgm
 2
every 3 weeks). Patients who developed PD within 90 days (PD/2;
n¼54) were subsequently enrolled to cetuximab plus cisplatin.
Objective responses were observed in 5, 3 and 9 patients with a
median response duration of 4.2, 4.1 and 7.4 months and a median
overall survival (OS) of 6.1, 4.3 and 11.7 months for the PD/1, PD/2
and SD groups, respectively. The most common toxicities were
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Figure 2 Preclinical and clinical development of Mabs and TKIs targeting
the EGFR in SCCHN. The Mabs (light grey arrows), tested to date, include
IMC-C225 (cetuximab), ICR62, ABX-EGF (panitumumab), EMD72000
(matuzumab), h-R3 (nimotuzumab), 2F8 (zalutumumab) and ch806.
Cetuximab (IMC-C225) has been approved for use in SCCHN by both
the FDA and EMEA in combination with radiotherapy. Nimotuzumab
(h-R3) was recently approved for head and neck cancer in Argentina, Cuba,
Columbia, China and India. ch806 is an EGFRvIII-specific Mab. Tyrosine
kinase inhibitors (dark grey arrows) in clinical development include the
EGFR inhibitors ZD1839 (gefitinib) and OSI-774 (erlotinib; formerly known
as CP-358-774) as well as the EGFR/HER-2 inhibitor GW572016
(lapatinib).
Table 1 Anti-EGFR Mab
Product Type
Ig
subclass Affinity (M) EGFR Epitope Rash Indications
Clinical
development Company
Cetuximab (IMC–C225) (Erbitux
R) Chimeric murine
Mab225
IgG1 3.9 10
 10 Domain III +++ HNC, CRC FDA/EMEA ImClone, Merck,
BMS
Nimotuzumab (h–R3) (TheraCIM
h–R3
R in North America)
(Theraloc
R in Europe)
(CIMAher in Latin America)
Humanised Mab
egf/r3
IgG1 10
 9–10
 10 Region 400–410
3A
  HNC, glioma Phase III Oncoscience,
Biotech Pharma,
YM Biosciences,
Biocon, CIMAB SA
Zalutumumab (2F8) (HuMax–EGFr
R) Human IgG1 +++ HNC Phase III Genmab A/S,
Medarex
Matuzumab (EMD72000) Humanised
EMD55900
Mab425
IgG1 3.4 10
 10 +++ Gastric, NSCLC Phase II Merck, Takeda
Panitumumab (ABX–EGF) Human IgG2 5 10
 11 +++ CRC, NSCLC Phase III Abgenix, Amgen
ICR62 Rat IgG2b Epitope C Phase I The Institute
ofCancer Research
(UK)
Ch806 Humanised
murine Mab806
IgG1 1.1 10
 9 Region 287–302
EGFRvIII
Phase I Ludwig Institute for
Cancer Research
(Melbourne)
CRC¼colorectal cancer; EGFR¼epidermal growth factor receptor; HNC¼head and neck cancer; Mab, monoclonal antibody; NSCLC¼non-small cell lung cancer. Cetuximab
has EMEA/FDA approval for treatment of metastatic CRC and was recently approved in combination with radiotherapy for the treatment of SCCHN. Nimotuzumab was
recently approved in combination with radiotherapy for nasopharyngeal cancer in China. It has also been approved for the treatment of HNC in Argentina, Columbia, Cuba and
India (July 2006).
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nausea/vomiting. Seven patients developed grade 3/4 hypersensi-
tivity reactions to cetuximab (Herbst et al, 2005).
Baselga et al (2005) reported another multicentre phase II trial
with 96 platinum-refractory SCCHN patients who received
cetuximab plus cisplatin (X60mgm
 2cycle
 1) or carboplatin
(X250mgm
 2cycle
 1). In the intent-to-treat population, the RR
was 10% with a disease control rate (DCR¼CRþPRþSD) of
53%. The median time to progression (TTP) was 85 days and OS
183 days, respectively. Treatment was well tolerated with skin
reactions being the most common cetuximab-related event.
Cetuximab also exhibited single-agent activity in platinum-
refractory SCCHN patients. In a multicentre phase II study with
103 evaluable patients, a 16.5% RR was reported. Median TTP and
OS were 85 and 175 days, respectively (Trigo et al, 2004).
In a phase III randomised multicentre placebo-controlled ECOG
trial in 117 metastatic/recurrent SCCHN patients, cetuximab plus
cisplatin (100mgm
 2 every 4 weeks) was compared with cisplatin
plus placebo (Burtness et al, 2005). The hazard ratio (HR) for
progression (primary end point) for the combination compared to
cisplatin plus placebo was 0.78 (95% CI, 0.54–1.12) with a median
PFS of 4.2 vs 2.7 months (P¼0.09), respectively. This was not
significant as the study was powered to detect a 50% reduction in
HRs. Furthermore, both arms had a significant drop-off rate and
the control arm performed better than expected. Median OS was
9.2 months for cisplatin plus cetuximab and 8.0 months for
cisplatin plus placebo (P¼0.21) and the objective RR was 26 vs
10%, respectively (P¼0.03). However, there was a survival
advantage for the development of rash (HR for survival by skin
toxicity in cetuximab-treated patients 0.42 (95% CI, 0.21–0.86)).
Zalutumumab (HuMax-EGFr
R, 2F8) was recently tested in a
phase I/II trial in 24 patients with recurrent/metastatic SCCHN
(0.15–8mgkg
 1 iv, after 28 days 4  weekly). Two PRs and eight
SDs were observed in 15 evaluable patients all occurring in the 1, 2,
4 and 8mgkg
 1 dose group (Bastholt et al, 2005). In January 2006,
FDA awarded Fast Track status to zalutumumab for HNC patients
who previously failed standard therapies. A pivotal phase III study
with zalutumumab in 273 SCCHN patients who are refractory to or
intolerant of standard platinum-based chemotherapy was initiated
in September 2006.
Anti-EGFR-Mabs in combination with radiotherapy In a phase I
study in locoregionally advanced SCCHN patients, cetuximab was
delivered in combination with conventional or hyperfractionated
RT (Robert et al, 2001). All patients achieved an objective response
(13 CRs and two PRs). The recommended dose for phase II/III
trials was 400–500mgm
 2 loading dose and 250mgm
 2 weekly
maintenance dose. A pilot phase II study of concurrent cetuximab,
cisplatin and concomitant boost radiotherapy for locoregionally
advanced SCCHN patients (n¼32) reported a 3-year OS of 75%,
PFS of 56% and a locoregional control rate of 71%. However, the
study was closed for significant AEs including two deaths (Pfister
et al, 2006). A randomised phase III study compared radiation with
or without cetuximab for patients with locally advanced inoperable
SCCHN patients (Bonner et al, 2006). The median duration of
locoregional control was 24.4 months among patients treated with
cetuximab plus radiotherapy and 14.9 months among those given
radiotherapy alone (HR for locoregional progression or death,
0.68; P¼0.005). With a median follow-up of 54.0 months, the
median OS was 49.0 months among patients treated with
combined therapy and 29.3 months among those treated with
radiotherapy alone (HR for death, 0.74; P¼0.03). Radiotherapy
plus cetuximab significantly prolonged PFS (HR for disease
progression or death, 0.70; P¼0.006). Cetuximab did not
significantly add to the acute side effects of radiotherapy, offering
a real therapeutic advantage to patients who are ineligible to
Table 2 Clinical trials of anti-EGFR antibodies for therapy of SCCHN
Drug Phase N Dosage Stage Response rate Reference
Anti-EGFR antibodies in combination with chemotherapy or as monotherapy:
Cetuximab
(IMC–C225)
I 26 5–100 (200–400) mgm
 2 SiD, MuD,
combination+cisplatin 60mgm
 24w
 1
Advanced PR
a 2 Baselga et al (2000)
Cetuximab
(IMC–C225)
Ib 12 100–500mgm
 2 LD 100–250mgm
 2 MD weekly
6w+cisplatin 100mgm
 23w
 1
Recurrent OR
a 67% (6/9) CR
a 2P R
a 4 Shin et al 2001)
Cetuximab
(IMC–C225)
II 132 400mgm
 2 LD 250mgm
 2 MD weekly 4 +cisplatin
75/100mgm
 23w
 1
Recurrent,
P-refractory
OR
a 13% (17/130) CR
a 2
PR
a 15 SD
a 66 DCR
a 64%
Herbst et al (2005)
Cetuximab
(IMC–C225)
II 96 400mgm
 2 LD 250mgm
 2 MD weekly+cisplatin/
Carboplatin
Recurrent,
P-refractory
OR
a 10% CR
a 0 DCR
a 53% Baselga et al (2005)
Cetuximab
(IMC–C225)
II 103 400mgm
 2 LD 250mgm
 2 MD weekly Recurrent,
P-refractory
OR
a 16.5% CR
a 5P R
a 12
SD
a38 DCR
a 53.4%
Trigo et al (2004)
Cetuximab
(IMC–C225)
III 117 A: C225+P B: placebo+P Recurrent/
metastatic
OR
b A26%/B10%
(p¼0.03) OS A 9.2/B
8.0m (n.s.)
Burtness et al (2005)
Zalutumumab
(2F8)
I–II 24 0.15–8mgkg
 1 d28 weekly Recurrent OR
b 12.5% PR
b 2S D
b 8 Bastholt et al (2005)
Anti–EGFR antibodies in combination with radiotherapy:
Cetuximab
(IMC–C225)
I 16 100–500mgm
 2 LD 100–250mgm
 2 MD for 7–8
weeks+RT (70 Gy, 2 Gy/d or 76.8 Gy, 1.2 Gy b.i.d.)
Advanced
untreated
OR
a 100% CR
a 13 PR
a 2 Robert et al (2001)
Cetuximab
(IMC–C225)
II 22 400mgm
 2 LD 250mgm
 2 MD weekly+boost
radiotherapy (70Gy)+cisplatin (100mgm
 2 w1+4)
Locoregionally
advanced
OR
a 15/16 CR
a 2P R
a 13
OS (3y) 76% PFS (3y) 56%,
LCR 71%
Pfister et al (2006)
Cetuximab
(IMC–C225)
III 424 A : radiotherapy B : radiotherapy+cetuximab 400mgm
 2
LD, 250mgm
 2 MD
Locoregionally
advanced
A : OS 29.3 mo. B : OS 49
mo.
Bonner et al (2006)
Nimotuzumab
(h–R3)
I 17 50–400mg weekly 6w+RT (60–66 Gy; 2 Gyd
 1) Advanced OR
b 87.5% (14/16) CR
b 9 Crombet et al (2004)
d¼day; CR¼complete remission; EGFR¼epidermal growth factor receptor; DCR¼disease control rate; LD¼loading dose; MD¼maintenance dose; mo.¼months;
MuD¼multiple doses; OR¼overall response rate; OS¼median overall survival; PFS¼median progression-free survival; PR¼partial remission; RT¼radiotherapy;
SCCHN¼squamous cell carcinomas of the head and neck; SD¼stable disease; SiD¼single dose; TTP¼median time to progression; w¼week; y¼year.
aWHO criteria;
bRECIST¼response evaluation criteria in solid tumours.
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cetuximab was approved by the FDA/EMEA in combination with
radiotherapy to treat SCCHN in February and April 2006.
However, this study did not compare cetuximab plus radiotherapy
with platinum-based radiotherapy, which is the current standard
of care. Additionally, radiotherapy was not uniformly administered
among all patients. These shortcomings are currently addressed in
RTOG trial 0522, which has been recently initiated and compares
chemoradiation with cisplatin to chemoradiation plus cetuximab.
Nimotuzumab (h-R3) has demonstrated clinical benefit without
rash development in several clinical trials. In a single-centre phase
I/II trial with 24 locally advanced SCCHN patients who received
6  weekly infusions (cumulative doses of 300, 600, 1200 and
2400mg) plus radiotherapy (60–66Gy), the combination was well-
tolerated with no skin or allergic toxicity (Crombet et al, 2004).
Nimotuzumab was recently approved for nasopharyngeal cancer in
China (April 2005), based on a 75% improvement in CR (91 vs
52%) in a phase II trial in 130 patients diagnosed with squamous
cell nasopharyngeal carcinoma who were treated with nimotuzu-
mab plus radiotherapy vs radiotherapy alone. It has also been
approved for the treatment of HNC in Argentina, Columbia, Cuba
and India (July 2006). A phase III trial in HNC is currently
ongoing.
EGFR TKIs
Numerous protein kinase inhibitors have been developed includ-
ing inhibitors of the EGFR kinase domain. Some molecules are
highly specific for EGFR (e.g. ZD1839, OSI-774), while others may
block additional Erb family kinases (e.g. GW572016, PKI-66) or
other protein kinase families (ZD6474). Both ZD1839 (Gefitinib)
and OSI-774 (formerly known as CP-358-774, Erlotinib) have FDA
approval for treatment of locally advanced or metastatic NSCLC
since May 2003 and November 2004, respectively. Three orally
active EGFR inhibitors have been tested in clinical trials in
recurrent/metastatic SCCHN or in combination with radiotherapy
in locoregionally advanced SCCHN (Table 3).
TKIs in recurrent/metastatic SCCHN
Gefitinib (Iressa
R, AstraZeneca Pharmaceuticals, London, UK)
impeded in vitro and in vivo growth of cell lines that express high,
intermediate or low levels of EGFR and high levels of HER-2.
Furthermore, gefitinib has additive or synergistic properties in
combination with cisplatin, carboplatin, paclitaxel, taxanes,
doxorubicin and radiotherapy. A phase II trial of 500mg gefitinib
in 52 patients with recurrent/metastatic SCCHN reported an RR
of 10.6% and a DCR of 53% (Table 3) (Cohen et al, 2003). Half the
cohort received gefitinib as second-line therapy. Median TTP and
OS were 3.4 and 8.1 months, respectively. The only grade 3 toxicity
encountered was diarrhoea (n¼3). Performance status and
development of skin toxicity were found to be strong predictors
of response, progression and survival. In another phase II trial,
gefitinib (500mgdose
 1, reduction to 250mg) was tested in 32
patients with recurrent SCCHN. In cohort A (no chemotherapy),
three PR and six SD were observed out of 20 patients (clinical
benefit in 45%). In cohort B (one previous chemotherapy), three
out of 12 patients achieved SD (25% clinical benefit). There was
no association between rash incidence/grade and clinical benefit
(Wheeler et al, 2005). An expanded access program with gefitinib
(500mgday
 1) in 47 SCCHN patients reported an 8% clinical RR
with 36% DCR. The median TTP and OS were 2.6 and 4.3 months,
respectively. Acneiform folliculitis was the most frequent toxicity
observed (76%) (Kirby et al, 2006). In another phase II trial with
gefitinib (250mgday
 1) in 70 SCCHN patients, two PRs and a 34%
DCR were observed. Median TTP and OS were 1.8 and 5.5 months,
respectively, with no difference between untreated and pretreated
patients. Gefitinib monotherapy at 250mgday
 1 in recurrent/
Table 3 Clinical trials of EGFR tyrosine kinase inhibitors for therapy of SCCHN
Drug Phase N Dosage Stage Response rate Reference
EGFR TKIs given as monotherapy or in combination with chemotherapy:
Gefitinib II 52 500mgday
 1 Rec./met. OR
b 10.6%, DCR
b 53% CR
b 1P R
b 4
SD
b 20 TTP 3.4 mo., OS 8.1 mo.
Cohen et al (2003)
Gefitinib II 32 250–500mgday
 1 A: no prior
chemotherapy B: one prior
chemotherapy
Rec. OR
b 9.4% A: PR
b 3S D
b 6 (20) B: SD
b 3
(12) TTP 3 mo., OS 6 mo.
Wheeler et al (2005)
Gefitinib ea 47 500mgday
 1 Rec./met. OR
b 8%, DCR
b 36% PR
b 4S D
b 13 TTP
2.6 mo., OS 4.3 mo.
Kirby et al (2006)
Gefitinib II 70 250mgday
 1 Rec./met. OR
b 1.4%, DCR
b 34% PR
b 1S D
b 23 Cohen et al (2005b)
TTP 1.8 mo. OS 5.5 mo.
Erlotinib II 115 150mgday
 1 Rec./met. OR
a 4.3%, DCR
a 38.3% PR
a 5S D
a 44
PFS 9.6 w, OS 6.0 mo.
Soulieres et al (2004)
Erlotinib+cisplatin, docetaxel II 37 150mgday
 1 Rec./met. OR
b 66% (21/32), DCR
b 91% CR
b 3
PR
b 18 SD
b 8
Kim et al (2006)
Lapatinib II 42 1500mgday
 1 Rec./met. A: naı ¨ve
B: TKI pre-treated
OR 0% SD A:37%; B:20% PFS A:1.6
mo.; B:1.7 mo.
Abidoye et al (2006)
EGFR TKIs in combination with radiotherapy:
Gefitinib+induction
chemotherapy followed by
radiochemotherapy
II 45 250mgqd
 1 Locally-advanced
unresectable
OR
a 85% (29/34) CR
a 11 PR
a 18 PFS
1.8 mo., OS 5.5 mo.
Doss et al (2006)
Erlotinib+radiochemotherapy
(docetaxel)
I2 3 1 5 m g m
 2 (50mgday
 1)
15mgm
 2 (100mgday
 1)
20mgm
 2 (100mg day
 1)
20mgm
 2 (150mgday
 1)
Locally-advanced Savvides et al (2006)
Lapatinib+radiochemotherapy I 17 500–1500mgday
 1 Locally-advanced Harrington et al (2006)
CR¼complete remission; DCR¼disease control rate (CR+PR+SD); ea¼expanded access programme; EGFR¼epidermal growth factor receptor; met.¼metastatic;
OR¼overall response rate (CR+PD); OS¼median overall survival; P¼cisplatinum; PFS¼median progression free survival; PR¼partial remission; rec.¼recurrent;
SCCHN¼squamous cell carcinomas of the head and neck; SD¼stable disease; TTP¼median time to progression.
aWHO criteria;
bRECIST¼response evaluation criteria in
solid tumours.
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observed for 500mg daily. Squamous cell carcinomas of the head
and neck responses to gefitinib or erlotinib seem not to be linked
to EGFR kinase mutational status, as these mutations are rare in
this disease (Cohen et al, 2005a,b). Recently, a phase I study in
SCCHN reported that gefitinib (250/500mg q.d.) in combination
with celecoxib (200/400mg b.i.d.) is very well tolerated in patients
with incurable SCCHN (Wirth et al, 2005).
Erlotinib (Tarceva
R; Roche, Genentech, OSI Pharmaceuticals)
has FDA/EMEA approval as single-agent treatment for patients
with locally advanced or metastatic NSCLC, and FDA approval in
combination with gemcitabine for first-line treatment of patients
with locally advanced, unresectable or metastatic pancreatic
cancer. A multicentre phase II trial of erlotinib in 115 patients
with recurrent and metastatic SCCHN reported a 4.3% overall RR,
including five PRs (Soulieres et al, 2004). Disease stabilisation was
maintained in 44 patients (38.3%) for a median duration of 16.1
weeks. Median PFS was 9.6 weeks and median OS was 6.0 months.
Rash (79%) and diarrhoea (37%) were the most common drug-
related toxicities. Skin rashes (4grade 2) correlated with longer
OS (7.4 months vs 4.0 (grade 0) or 5.0 months (grade 1)). Recently,
a phase I study in SCCHN reported that erlotinib (150mgqd) in
combination with bevacizumab (5, 10 and 15mgkg
 1 i.v. 3q
weeks) is feasible and well tolerated in patients with recurrent/
metastatic SCCHN (Mauer et al, 2004). In a phase II trial of
erlotinib (150mgp.o.) plus cisplatin/docetaxel in recurrent/meta-
static SCCHN, 66% ORR (three CRs, 18 PRs, eight SDs) and 91%
DCR were observed. Grade 3/4 toxicities included neutropenia,
diarrhoea and rash (Kim et al, 2006).
Lapatinib (Tykerb
R, GW572016, GlaxoSmithKline, Brentford,
London, UK) is a selective kinase inhibitor of both EGFR and
HER-2. A phase II trial of lapatinib (1500mg o.d.) in recurrent/
metastastic SCCHN reported no objective responses, suggesting
little activity in either EGFR inhibitor naı ¨ve or refractory patients
(Abidoye et al, 2006) (Table 3).
TKIs in combination with radiotherapy
A phase I/II study combining gefitinib (250mg p.o. q.d.) with
induction chemotherapy (docetaxel/5-FU/carboplatin) in locally
advanced SCCHN demonstrated that this regimen was feasible
and produced high RR (11 CRs, 18 PRs, five SDs out of 34 patients)
(Doss et al, 2006). Two phase I/II studies of erlotinib in
combination with docetaxel or cisplatin and radiotherapy in
locally advanced SCCHN demonstrated that these combinations
are safe and feasible (Herchenhorn et al, 2006; Savvides et al,
2006). Phase II trials are planned or ongoing (Table 4). Recently,
results from an ongoing phase I study of lapatinib in combination
with cisplatin (100mgm
 2 days 1, 22, 43) plus radiotherapy (66–
70Gy/6–7 weeks) in locally advanced SCCHN demonstrated minor
AEs and encouraging clinical activity (Harrington et al, 2006).
Rash and clinical outcome
Acneiform papulopustular skin rash, usually on the face and upper
torso, is the most common toxicity found with EGFR antibodies
such as cetuximab, panitumumab or matuzumab and the kinase
inhibitors gefitinib and erlotinib (Perez-Soler and Saltz, 2005).
Table 4 Ongoing clinical trials targeting the EGFR in SCCHN (www.clinicaltrials.com)
Drug Phase SCCHN/Stage N Sponsor
TKIs as monotherapy or in combination with chemotherapy:
Erlotinib II Recurrent/metastatic 37 NCI
Erlotinib+docetaxel I/II Recurrent/metastatic 15/36 Ohio State Univ. NCI
Erlotinib7bevacizumab I/II Advanced 30 Duke Univ. Genentech./OSI
Erlotinib+docetaxel+cisplatin II Recurrent/metastatic 50 MD Anderson CC
Docetaxel7gefitinib III Recurrent/metastatic 330 ECOG
Lapatinib II Recurrent/metastatic 15–30 Univ. Virginia NCI
Lapatinib II Recurrent/metastatic 40–88 Univ. Chicago NCI
TKIs in combination with radiotherapy:
Erlotinib+cisplatin ia+RTX II Locally-advanced 20 Southern Illinios Univ. Genentech./OSI
Erlotinib+RTX7cisplatin I Stage II–IV 24–48 Sidney Kimmel CC NCI
Erlotinib+docetaxel+RTX I Locoregionally advanced 24 MD Anderson CC Sanofi-Aventis Genentech
Adjuvant Erlotinib after RCTX I Locally-advanced 6–20 NCI Canada
Gefitinib +RTX II Locally-advanced inoperable 28 AstraZeneca
Gefitinib+cisplatin+RTX I/II Locally-advanced 40 AstraZeneca
Gefitinib+cisplatin+Re-RTX I Locoregional recurrent 10 Stanford Univ. AstraZeneca
Gefitinib+cisplatin+RTX0 I/II Unresectable 29 Cornell Univ.
Gefitinib+Paclitaxel+RTX I Advanced/recurrent 15–30 NCI
Gefitinib+cisplatin+RTX I/II Locally-advanced 40 AstraZeneca
Gefitinib+RTX7cisplatin I Stage III/IV 30 Univ. Colorado
Gefitinib+Paclitaxel+RTX I Advanced/recurrent 15–30 NCI
Cisplatin+RTX7Gefitinib concomitant or maintenance II Stage III/IV 224 AstraZeneca
Anti-EGFR monoclonal antibodies as monotherapy or in combination with chemotherapy:
Cetuximab+albumin bound paclitaxel (¼Abraxanet) II Recurrent/metastatic Univ. California Irvine
Cetuximab+cisplatin or carboplatin and 5-fluorouracil (EXTREME trial) III Recurrent/metastatic 440 Merck
Anti-EGFR monoclonal antibodies in combination with radiotherapy:
Cisplatin+RTX7Cetuximab III Stage III/IV 720 RTOG/NCI
Cetuximab+Pemetrexed+RTX I Recurrent 40 Univ. Pittsburg Lilly Bristol-Myers Squibb
Adjuvant Cetuximab+cisplatin vs docetaxel+RTX II Stage III/IV 230 RTOG
Cetuximab+cisplatin+RTX II Stage III/IV 68 ECOG/NCI
Cetuximab+cisplatin/docetaxel before Cetuximab+cisplatin/RTX II Locally-advanced 40 Univ. Pittsburg Bristol-Myers Squibb
Cetuximab+Concomitant-Boost accel. RTX II Locally-advanced oropharyngeal 90 Merck
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no grade 4. Phase I studies indicate that rash is dose dependent.
Data from multiple studies with cetuximab, erlotinib and gefitinib
show a consistent relationship between rash and response or
survival (Cohen et al, 2003, 2005a,b; Soulieres et al, 2004; Baselga
et al, 2005; Burtness et al, 2005; Herbst et al, 2005). Little is known
about the aetiology of the rash and evidence-based treatment
recommendations for rash management are missing owing to the
lack of clinical trials addressing this problem (Perez-Soler and
Saltz, 2005). Recently, results from a prospective algorithmic
approach for the treatment of skin rash in SCCHN patients was
presented (Garey et al, 2005) (Table 5). Responses included 11 out
of 11 CRs for grade 1, three out of four PRs for grade 2 and one PR
for grade 3 rash.
CONCLUSIONS AND FUTURE PERSPECTIVES
Clinical trials treating SCCHN patients with molecularly targeted
treatment strategies designed to specifically inhibit EGFR function
have shown promising – albeit limited – levels of efficacy, even as
monotherapy. Food and Drug Administration/EMEA approval of
cetuximab, in combination with radiotherapy for SCCHN treat-
ment, represents the first new drug registration to treat HNC since
methotrexate became available in the 1950s. Cetuximab or TKIs
plus radiotherapy have a more favourable toxicity profile when
compared to chemoradiotherapy. Multiple phase I/II trials are
currently testing combinations of cetuximab or TKIs with
chemoradiotherapy in locoregionally advanced SCCHN (Table 4).
In recurrent/metastatic SCCHN, cetuximab and three TKIs are
currently investigated as monotherapy or in combination with
chemotherapy. Owing to high toxicity with cisplatin combinations,
taxane regimens may be more feasible. These combination
therapies may lead to the use of lower doses of standard
chemotherapeutics and thus reduced non-specific toxicity to
patients, without loss of anticancer activity. Cisplatin-refractory,
recurrent/metastatic SCCHN patients may also benefit from
EGFR-targeting strategies.
Interestingly, dual-agent molecular targeting of the EGFR
combining cetuximab with TKIs (e.g. gefitinib, erlotinib) enhanced
tumour growth inhibition over that observed with either agent
alone (Huang et al, 2004; Matar et al, 2004). However, others have
found that combination of cetuximab and gefitinib was anta-
gonistic in all cell lines considered, suggesting that a double-hit
strategy with Mabs and TKIs must be considered with caution
(Fischel et al, 2005). Another strategy may be combination of
EGFR antagonists (Mab or TKI) with inhibitors of RAS or
phosphatidyl inositol-3 kinase pathways, which are downstream
of the EGFR (e.g. PI3K inhibitor LY294002, MEK inhibitor U0126,
mevalonate pathway inhibitor lovastatin or farnesyl transferase
inhibitor FTI SCH66336). Furthermore, inhibitors of VEGF
signalling (e.g. bevacizumab, sorafenib, AZD2171) may be potent
partners for novel combination therapies (Table 4). Other
potentially interesting targets are EGFR-independent survival
pathways (e.g. insulin-like growth factor-1 (IGF-1R)) or GPCRs
that mediate their effects through EGFR.
Although anti-EGFR-targeted therapies may lead to PRs and
disease stabilisation in some patients, many patients do not benefit
from these therapies and responsive cases may eventually develop
resistance. Molecular resistance mechanisms include (1) specific
EGFR mutations (e.g. EGFRvIII, T790M), (2) constitutive activa-
tion of downstream effectors (e.g. loss/inactivation of PTEN,
activation of Src, RAS, STAT3/5), (3) increased angiogenesis
(upregulation of VEGF) and (4) the presence of redundant
tyrosine kinase receptors (e.g. HER-2, c-MET, IGF-1R) (Kobayashi
et al, 2005). Many anti-EGFR Mabs are unable to bind the
aberrant extracellular domain of EGFRvIII and thus fail to
inhibit ligand-induced receptor activation. Interestingly, resistance
caused by the T790M mutation can be overcome by CL-387785, a
specific and irreversible anilinoquinazoline EGFR inhibitor
(Kobayashi et al, 2005). Another major challenge is the
development of reliable methods to determine which patient
populations are likely to receive the greatest benefit from these
novel agents in order to justify the enormous treatment costs of
these new drugs.
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